

## Fact Sheet

|                       |  |
|-----------------------|--|
| Name                  | <b>InfectoPharm Arzneimittel und Consilium GmbH</b>  |
| Sector                | Pharmaceutical industry  |
| Type                  | Family-owned company, in second generation   |
| Target markets        | Pharmaceuticals for children (pediatrics, social pediatrics)<br>Infectiology, dermatology, pneumology, allergology, ENT<br>Special preparations for use in hospitals<br>Over-the-counter products for self-medication (OTC)<br>Medicinal products<br>Cosmetics |
| Core                  | Development and continuous improvement of pharmaceuticals with medically proven active ingredients   |
| Market leader Germany | Pediatrics: strong in infectiology, dermatology and ENT  |
| USP                   | <i>consilium</i> service – impartial consulting, training and knowledge transfer for physicians and other healthcare professionals in Germany  |
| Guiding principle     | "Knowledge is Health"  |
| Headquarter           | Heppenheim (Hesse), Germany  |
| Founded in            | 1988   |
| Founder               | Dr. Manfred Zöller <sup>†</sup> and Monika Zöller  |
| Management Board      | Philipp Zöller – Strategy, Business Development<br>Michael Gilster – Business Administration, IT, Logistics<br>Dr. Markus Rudolph – Marketing & Sales, International Business<br>Dr. Aldo Ammendola – Manufacturing, Research & Development                    |
| Size:                 | > 470 InfectoPharm Group   |
| Number of employees   | ~ 300 InfectoPharm Germany, ~ 110 Beyvers<br>~ 40 in subsidiaries: Austria, Italy, France, Poland, Great Britain   |
| Revenue               | ~ 330 mill. euros InfectoPharm Group (2025)  |
| Annual growth rate    | ~ 10 %   |
| International         | Sales to >30 countries, main target area is Europe   |
| Products              | > 140, of which ~80 are prescription-only pharmaceuticals<br>> 400 Marketing Authorisations (pharmaceuticals)<br>~ 100 (others)  |

|               |  |
|---------------|--|
| Subsidiaries  | <b>Pädia GmbH</b> , Heppenheim (OTC products for children)<br><a href="http://www.paedia.de">www.paedia.de</a>   |
|               | <b>Beyvers GmbH</b> , Berlin (CMO for liquids and semi-liquids)<br><a href="http://www.beyvers.de">www.beyvers.de</a>  |
|               | <b>InfectoPharm Digital Health GmbH</b> , Hamburg (Digital Health Solutions)<br><a href="http://www.meinetinnitusapp.de/unternehmen">www.meinetinnitusapp.de/unternehmen</a> |
| International | <b>InfectoPharm Arzneimittel und Consilium GmbH</b><br>Vienna, Austria<br><a href="http://www.infectopharm.at">www.infectopharm.at</a>                                       |
|               | <b>InfectoPharm Srl</b><br>Milan, Italy<br><a href="http://www.infectopharm.it">www.infectopharm.it</a>  |
|               | <b>InfectoPharm France SAS</b><br>Lyon, France<br><a href="http://www.infectopharm.fr">www.infectopharm.fr</a>   |
|               | <b>InfectoPharm Ltd</b><br>London (Marlow), United Kingdom<br><a href="http://www.infectopharm.co.uk">www.infectopharm.co.uk</a>   |
|               | <b>InfectoPharm Polska Sp. Z o.o.</b><br>Warsaw, Poland  |
| Cooperations  | Vaccine alliance with msd  |

Last update: 02.2026

## About InfectoPharm

InfectoPharm Arzneimittel und Consilium GmbH specializes in the initial and further development of pharmaceuticals. Over the last 35 years, this family-owned German company has established itself as a groundbreaking pioneer in the industry. The portfolio currently comprises about 140 preparations – including numerous innovations in the fields of pediatrics, infectious diseases, pulmonology, dermatology, allergology, and otolaryngology. The “*consilium* service” provides impartial consulting and knowledge transfer to healthcare professionals, free of charge.

The InfectoPharm Group owns branches in Austria, Italy, the United Kingdom, France, and Poland as well as three strategically complementary subsidiaries in Germany: Pädia GmbH with its distinct pediatric OTC portfolio, and Beyvers GmbH as an internationally known full-service supplier for pharmaceuticals and cosmetics. The third promising acquisition in 2025 is InfectoPharm Digital Health GmbH with a well-established tinnitus app as a modern health solution. The group has more than 470 employees and posts an annual turnover of approximately 330 million euros (2025), with an average growth rate of 10 percent. InfectoPharm regularly receives awards from the medical community, such as the “Golden Tablet”, and from the business sector, for example as the “Most Crisis-Proof Employer”, “Most Crisis-Proof Company”, and “Most Innovative Company”.